News

Foresight has reported the dosing of first patient in a viral conjunctivitis clinical trial. Foresight’s lead compound, FST-100, will be tested in a placebo-controlled, masked, and randomized multicenter

Osiris has received a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF), for progress made on a phase II clinical trial. The study is to evaluate

Shire has received a Complete Response letter for INTUNIV (guanfacine) Extended Release from FDA. Reportedly, FDA did not identify safety concerns regarding INTUNIV in the letter about the

GeneGo has received grant from Natinal Institute of Health to develop an integrated systems pharmacology platform for pharmacogenomic research. The Small Business Innovation Research (SBIR) grant will be

Boehringer Ingelheim has posted growth in local currency (+8.3%) in the first six months of 2009, as compared to the corresponding period previous year. The company reported net

Nuevolution has reported the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline (GSK). Reportedly, the agreement relates to a number of patented technologies for rapid synthesis and

Wyeth (WKK), ASKA and Takeda have reported changes to the Japanese distribution, sales and promotion for WKK’s transdermal absorption-type analgesic and anti-inflammatory agent, SELTOUCH Pap 70, 140 (SELTOUCH).

PTC has initiated a phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant

FDA has granted an emergency use authorization to Quest Diagnostics’ Focus Diagnostics Business for its test to detect the 2009 H1N1 influenza virus, a strain of influenza A